Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo/Active Controlled, Single Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Patients with Various Allergic Diseases

NCT05960708 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT05960708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05960708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo/Active Controlled, Single Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Patients with Various Allergic Diseases
Lead sponsor
Yuhan Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 23, 2023
Completion date
September 13, 2024
Enrollment
30 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

allergic disease, chronic inducible urticaria, chronic spontaneous urticaria, cold urticaria